View Older Stories View More Recent Stories
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
Form SC 13G Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nkarta (NKTX) Prices $240M Share and Warrant Offering at $10/sh
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
LENZ Therapeutics (LENZ) Completes Merger with Graphite Bio, Provides Update
-
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
-
Capstan Therapeutics Announces $175M Oversubscribed Series B Financing
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
-
Cybin Inc (CYBN) Closes $150M Share Placement
-
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
-
Geron Corp (GERN) Prices $150M Share and Warrant Offering at $3/sh
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
-
Cybin Inc (CYBN) Announces $150M Oversubscribed Private Placement at $0.43/sh
-
Announces Oversubscribed Private Placement of U.S. $150 Million
-
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Form SC 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth
-
Lexeo Therapeutics (LXEO) Announces Oversubscribed $95.0 Million Equity Financing
-
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
-
Graphite Corp. (GRPH) Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
-
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Aerovate Therapeutics (AVTE) Appoints Habib Dable as Board Chair
-
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
-
Avidity Biosciences Inc. (RNA) Prices 15.22M Share Offering at $16.50/sh
-
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
-
Form SC 13D/A Connect Biopharma Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics to Participate in Upcoming Investor Conferences
-
Form SC 13G Larimar Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
-
Form SC 13D/A Icosavax, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A NEKTAR THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
